1-(4-氯苯基)-5-甲基-吡唑-4-羧酸 | 187998-35-2

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(4-氯苯基)-5-甲基-吡唑-4-羧酸
• 中文别名: 1-(4-氯苯基)-5-甲基-1H-吡唑-4-羧酸
• 英文名称: 1-(4-chlorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid
• 英文别名: 1-(4-chlorophenyl)-5-methylpyrazole-4-carboxylic acid
• CAS: 187998-35-2
• 化学式: C₁₁H₉ClN₂O₂
• mdl: MFCD01566260
• 分子量: 236.658
• InChiKey: OAPQKGGVDCZENK-UHFFFAOYSA-N

物化性质

• 熔点：
  201 °C
• 沸点：
  406.3±35.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933199090
• 危险性防范说明：
  P261,P280,P302+P352,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	1-(4-Chlorophenyl)-5-methyl-1h-pyrazole-4-carboxylic acid 97% Material Safety Data Sheet
Synonym:
CAS:	187998-35-2

Section 1 - Chemical Product MSDS Name:1-(4-Chlorophenyl)-5-methyl-1h-pyrazole-4-carboxylic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
187998-35-2	1-(4-Chlorophenyl)-5-methyl-1H-pyrazol	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 187998-35-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: grey
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 196 - 198 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H9ClN2O2
Molecular Weight: 236.66

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 187998-35-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(4-Chlorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 187998-35-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 187998-35-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 187998-35-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(4-氯苯基)-5-甲基-吡唑-4-羧酸 在 4-二甲氨基吡啶 copper(l) iodide 、 氯化亚砜 、 cesium acetate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 34.0h， 生成 1-(4-chloro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid [1-(5-methanesulfonylamino-pyridin-3-yl)-butyl]-amide
  参考文献：
  名称：

  [EN] PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS
  [FR] COMPOSÉS DE PYRAZOLE COMME ANTAGONISTES DE CCR1

  摘要：

  公开的是公式I的化合物，它们可以阻断CCR1与其配体的相互作用，因此可用于治疗通过CCR1的活性介导或维持的各种疾病和疾病，包括类风湿性关节炎和多发性硬化等自身免疫疾病。还公开了包括这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。

  公开号：

  WO2009137338A1
• 作为产物：
  描述：

  1-(4-chlorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid ethyl ester 在 乙醇 、 potassium hydroxide 、 盐酸 作用下， 以 水 为溶剂， 反应 3.5h， 以91%的产率得到1-(4-氯苯基)-5-甲基-吡唑-4-羧酸
  参考文献：
  名称：

  吡唑的 N-杂环卡宾重排为 4-氨基喹啉和苯并喹啉

  摘要：

  1-苯基取代的吡唑鎓盐，由吡唑与苄基卤化物或长链烷基卤化物的季铵化形成，去质子化为吡唑-3-亚基，经过一系列开环、闭环和互变异构化为新的取代的4-氨基喹啉。类似地，1-萘基取代的吡唑鎓-3-羧酸盐在甲苯中加热时脱羧，通过类似的反应途径以优异的产率得到苯并喹啉。DFT 计算表明，环转化通过一系列分子内消除、亚胺反转和 6π-电环化步骤进行。

  DOI：

  10.1002/ejoc.201000507

文献信息

• Inhibitors of cathepsin S
  申请人：IRM LLC

  公开号：US20040198780A1

  公开（公告）日：2004-10-07

  The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., cathespin K). The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.

  本发明提供了用于选择性抑制蛋白酶S的化合物、组合物和方法。在一个优选方面，当至少存在另一种蛋白酶同工酶（例如，蛋白酶K）时，选择性地抑制蛋白酶S。本发明还提供了通过选择性抑制蛋白酶S来治疗受试者疾病状态的方法。
• [EN] 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK<br/>[FR] AMIDES HÉTÉROCYCLIQUES À 5 CHAÎNONS ET BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE ROCK
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019014308A1

  公开（公告）日：2019-01-17

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了化合物的结构式（I）：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。
• Pyrazole-amides and sulfonamides as sodium channel modulators
  申请人：Atkinson N. Robert

  公开号：US20050020564A1

  公开（公告）日：2005-01-27

  Compounds of the present invention modulate PN3 in mammals and are useful in treating pain in mammals.

  本发明的化合物调节哺乳动物中的PN3，并且在治疗哺乳动物的疼痛方面是有用的。
• 롤 화장지 인출장치
  申请人：HAN MOON KYO 한문교(419980413753)

  公开号：KR20150002661U

  公开（公告）日：2015-07-08

  본 고안은 롤 화장지 걸이대에 간편하게 장비되어 롤 화장지를 사용자가 필요한 길이로 감아 절취한 상태에서 측면 이탈 시에 구김이나 찢김 없이 용이한 인출이 제공되어 편리성이 보장되는 롤 화장지 인출장치를 제공하는 것을 목적으로 하고 있다. 본 고안의 상기 목적은 벽체에 설치되는 케이스의 내부 상측에 구비된 롤축에 중심지관으로 끼움 된 롤 화장지를 케이스의 하부로 인출하여 ‘ㄷ’자형 회전날개에 의해 소정 길이로 감고, 상기 회전날개에 감겨진 화장지를 측면으로 빼내 사용하도록 롤 화장지의 인출장치에 있어서, 상기 ‘ㄷ’자형 회전날개의 내측에 다른 ‘ㄷ’자형의 지지날개를 구비하여 상호 간이 교차 상태로 하여 각각의 회전날개와 지지날개의 외주에 롤 화장지를 소정 길이로 권취한 후 절취하고, 상기 지지날개의 역 회전에 의해 롤 화장지의 감김상태를 느슨하게 한 상태에서 측면으로 빼어 사용할 수 있도록 구성한 것을 특징으로 하는 롤 화장지 인출장치에 의해 달성된다..

  该设想旨在提供一种方便使用者将卷纸卫生纸卷取到所需长度并剪断后，当侧面脱落时能够轻松取出而无褶皱或撕裂的卷纸卫生纸取出装置，以确保便利性。该设想的上述目的通过提供一种卷纸卫生纸取出装置实现，该装置包括在安装在墙体上的盒体内部上侧配备的卷芯，通过将装有卷纸卫生纸的卷芯插入盒体底部以提取，并通过“ㄷ”字形旋转翼片将其卷成适当长度，然后从侧面取出使用的卷纸卫生纸取出装置，其中，在卷纸卫生纸取出装置中，通过在“ㄷ”字形旋转翼片的内侧配备另一个“ㄷ”字形支撑翼片，使其相互交叉状态，然后在每个旋转翼片和支撑翼片的外周上将卷纸卫生纸卷取到适当长度后剪断，并通过支撑翼片的反向旋转使卷纸卫生纸的卷曲状态变松，从而使其能够从侧面取出并使用。
• Acylated indanyl amines and their use as pharmaceuticals
  申请人：——

  公开号：US20030055093A1

  公开（公告）日：2003-03-20

  The present invention relates to acylated indanyl amines according to the general formula (I) 1 wherein R 1 -R 4 have the meanings given in the description, A is CH 2 , CHOH or CH—(C 1 -C 3 -alkyl), B is CH 2 or CH—(C 1 -C 3 -alkyl), and R 5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description. These compounds are useful in the upregulation of endothelial nitric oxide synthase (eNOS), and may therefore be useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes or diabetes complications, nephropathy or retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.

  本发明涉及通式（I）中的酰化的茚基胺，其中R1-R4具有描述中给出的含义，A为CH2、CHOH或CH—（C1-C3-烷基），B为CH2或CH—（C1-C3-烷基），R5为芳基或杂芳基，可能被描述中列出的取代基取代。这些化合物在上调内皮型一氧化氮合酶（eNOS）方面有用，因此可能用于制造用于治疗心血管疾病、稳定或不稳定心绞痛、冠心病、普林兹梅塔心绞痛、急性冠状综合征、心力衰竭、心肌梗死、中风、血栓形成、周围动脉闭塞性疾病、内皮功能障碍、动脉粥样硬化、再狭窄、PTCA后内皮损伤、高血压、原发性高血压、肺动脉高压、继发性高血压、肾血管性高血压、慢性肾小球肾炎、勃起功能障碍、室性心律失常、糖尿病或糖尿病并发症、肾病或视网膜病变、血管生成、支气管哮喘、慢性肾功能衰竭、肝硬化、骨质疏松症、记忆力受限、学习能力受限，或用于降低绝经后妇女或口服避孕药后心血管风险。